Unveiling the RX for Success 2024 – Tracking Pharma & Biotech Stock Performance

Highlights of the report

The global pharmaceutical and biotechnology (pharma & biotech) industry showed remarkable resilience in 2023, recovering strongly from the temporary slowdown caused by the COVID-19 pandemic.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

The convergence of science and technology is driving innovation in the biopharma industry. AI-led discovery is fueling new sustainable growth opportunities. In fact, total investment in AI-mediated drug discovery has experienced a CAGR of 8% and closed 2022 with a total of $2.5bn worth of investment.

Total global spending on medicines is projected to exceed $1.9 trillion by 2027, indicating a healthy compound annual growth rate (CAGR) of 3-6% from 2023 onwards. This growth will be driven initially by spending on
therapeutics, followed by a rebound in non-COVID drugs.

The global pharmaceutical manufacturing market demonstrated robust growth of 12% in 2023 to reach $508bn in revenues. Key factors propelling growth include rising demand for prescription medications, aging populations that require more treatments, and increasing demand from healthcare systems and patients worldwide for innovative therapies that can address unmet medical needs.

Executive Summary

– Key Highlights
– Market Overview
– Technological Trends
– M&A
– R&D
– Therapy Area
– Oncology
– Cardiology
– Immunology
– Anti-diabetic
– Neurology
– CrispIdea Outlook
– Conclusion
– Index and Stock Performance

Key Players

– AbbVie Inc
– Sanofi SA
– Dr Reddy’s Laboratories Ltd
– Regeneron Pharmaceuticals Inc
– Eli Lilly And Co
– Moderna Inc
– Baxter International Inc
– Stryker Corp
– Bausch Health Companies Inc
– Zoetis Inc
– Amgen, Inc.
– Pfizer Inc.
– Tilray Brands Inc
– BioNTech SE – ADR
– Gilead Sciences, Inc.
– Biogen Inc
– Teva Pharmaceutical Industries Ltd
– Becton Dickinson and Co
– AstraZeneca plc
– Johnson & Johnson
– Merck & Co


This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.

Report details

Unveiling the RX for Success 2024 – Tracking Pharma & Biotech Stock Performance



Company Reports

Sector Reports